Diabetes, vascular complications and antiplatelet therapy: Open problems

Acta Diabetologica

Volumn 46, Issue 4, 2009, Pages 253-261

  Cerbone, A M ^a   MacArone Palmieri, N ^a   Saldalamacchia, G ^a   Coppola, A ^a   Di Minno, G ^a   Rivellese, A A ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Angiopathy; Antiplatelet; Diabetes

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOBUFEN; INSULIN; PICOTAMIDE; PLACEBO; TICLOPIDINE; TIROFIBAN;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG METABOLISM; HEART INFARCTION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; LOW DRUG DOSE; PRESCRIPTION; PRIORITY JOURNAL; RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOCYTE DYSFUNCTION; THROMBOSIS; UNSTABLE ANGINA PECTORIS; UREMIA; VASCULAR DISEASE;

ASPIRIN; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 70449523675     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-008-0079-y     Document Type: Article

References (92)

1. TF Luscher MA Creager JA Beckman F Casentino 2003 Diabetes and vascular disease: pathophysiology, clinical consequences and medical therapy Circulation 108 1655 1661 10.1161/01.CIR.0000089189.70578.E2 14517152 (Pubitemid 37187795)
2. J Stamler O Vaccaro JD Neaton D Wentwort 1993 Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial Diabetes Care 16 434 444 10.2337/diacare.16.2.434 8432214
3. RW Nesto 2004 Correlation between cardiovascular disease and diabetes mellitus current concepts Am J Med 116 5 11S 22S 10.1016/j.amjmed.2003.10.016 15019859 (Pubitemid 38333037)
4. UKPDS Group 1990 UK Prospective Diabetes Study 6: complications in newly diagnosed type II diabetic patients and their association with different clinical and biochemical risk factors Diabetes Res 13 1 11
5. JA Beckman MA Creager P Libby 2002 Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2570 2581 10.1001/jama.287.19.2570 12020339
6. C Watala 2005 Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus Curr Pharm Des 11 2331 2365 10.2174/1381612054367337 16022671 (Pubitemid 40872701)
7. JA Colwell PD Winocour PV Halushka 1983 Do platelets have anything to do with diabetic microvascular disease? Diabetes 32 Suppl 2 14 19 6242836
8. P Ferroni S Basili A Falco G Davi 2004 Platelet activation in type 2 diabetes mellitus J Thromb Haemost 2 1282 1291 10.1111/j.1538-7836.2004.00836.x 15304032 (Pubitemid 40186123)
9. G Davi I Catalano M Averna A Notarbartolo A Strano G Ciabattoni C Patrono 2001 Thromboxane biosynthesis and platelet function in type II diabetes mellitus N Engl J Med 322 1769 1774
10. JM Bridges AM Dalby JHD Millar JA Weaver 1965 An effect of d-glucose on platelet stickiness Lancet 1 75 77 10.1016/S0140-6736(65)91656-9 14234204
11. A D'Angelo P Micossi PM Mannucci P Garimberti F Franchi G Pozza 1984 Increased production of platelet thromboxane B2 in non-insulin-dependent diabetes: relationship to vascular complications Eur J Clin Invest 14 83 86 10.1111/j.1365-2362.1984.tb02092.x 6428908
12. C Watala M Boncler P Gresner 2005 Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus Pharmacol Rep 57(Suppl) 42 58
13. HJ Oskarsson TG Hofmeyer 1996 Platelet from diabetic patients with diabetes mellitus have impaired ability to mediate vasodilatation J Am Coll Cardiol 27 1464 1470 10.1016/0735-1097(96)00019-8 8626959 (Pubitemid 26151682)
14. G Davi M Belvedere S Vigneri I Catalano C Giammarresi S Roccaforte A Consoli A Mezzetti 1996 Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus Thromb Haemost 76 34 37 8819248
15. AD Michelson M Cattaneo, et al.. 2005 Aspirin-resistance: position paper of the working group on aspirin resistance J Thromb Haemost 3 1309 1311 10.1111/j.1538-7836.2005.01351.x 15892858 (Pubitemid 41725257)
16. G Di Minno MJ Silver AM Cerbone S Murphy 1986 Trial of repeated low-dose aspirin in diabetic angiopathy Blood 68 886 891
17. JM Gerrard MJ Stuart GHR Rao MW Steffes SM Mauer DM Brown JG White 1980 Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats J Lab Clin Med 95 950 958 6445927
18. R Jokl JA Colwell 1997 Arterial thrombosis and atherosclerosis in diabetes Diabetes Metab Rev 5 1 15
19. JA Colwell RW Nesto 2003 The platelets in diabetes Diabetes Care 26 2181 2188 10.2337/diacare.26.7.2181 12832332
20. ETDRS Investigators 1992 Aspirin effects on mortality and morbidity in patients with diabetes mellitus J Am Med Assoc 268 1292 1300 10.1001/jama.268.10.1292
21. Antiplatelet trialists' Collaboration 1994 Collaborative overview of randomised trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various category of patients Br Med J 308 81 106
22. Antithrombotic Trialist' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients Br Med J 324 71 86 10.1136/bmj.324.7329.71
23. ISIS 2 1988 Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study Of Infarct Survival) collaborative group Lancet 2 349 360
24. JA Colwell 1997 Aspirin therapy in diabetes Diabetes Care 20 1767 1771 9353620
25. Steering Committee of the Physicians' Health Study Research Group 1989 Final report on the aspirin component of the ongoing Physicians' Health Study N Engl J Med 321 129 135
26. L Hansson A Zanchetti SG Carruthers B Dahlof D Elmfeldt S Julius J Menard KH Rahn H Wedel S Westerling 1998 Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: HOT study group Lancet 351 1755 1762 10.1016/S0140-6736(98)04311-6 9635947 (Pubitemid 28269185)
27. Collaborative group of the Primary Prevention Project 2001 Low dose aspirin and vit E in people at cardiovascular risk: a randomized trial in general practice Lancet 357 89 95 10.1016/S0140-6736(00)03539-X (Pubitemid 32094910)
28. M Sacco F Pellegrini MC Roncaglioni F Venzini G Tognoli A Nicolucci 2003 On behalf of the PPP collaborative group primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients Diabetes Care 26 3264 3272 10.2337/diacare.26.12.3264 14633812 (Pubitemid 37466885)
29. HA Arjomand B Roukoz SK Surabhi M Cohen 2003 Platelets and antiplatelet therapy in patients with diabetes mellitus J Invasive cardiol 15 264 269 12730635
30. JB Buse, et al.. 2007 Primary prevention of cardiovascular diseases in people with diabetes mellitus Diabetes Care 30 162 172 10.2337/dc07-9917 17192355 (Pubitemid 46052519)
31. JB Buse, et al.. 2007 Primary prevention of cardiovascular diseases in people with diabetes mellitus Circulation 115 114 126 10.1161/CIRCULATIONAHA. 106.179294 17192512 (Pubitemid 46058619)
32. American Diabetic Association Position Statement 2000 Aspirin therapy in diabetes Diabetes Care 23 61S 62S
33. TA Pearson SN Blair SR Daniels RH Eckel JM Fair SP Fortmann BA Franklin LB Goldstein P Greenland SM Grundy Y Hong NH Miller RM Lauer IS Ockene RL Sacco JF Sallis Jr SC Smith Jr NJ Stone KA Taubert 2002 AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA scientific statement) Circulation 106 388 391 10.1161/01.CIR.0000020190.45892.75 12119259 (Pubitemid 34778969)
34. DL Bhatt SP Marso AT Hirsch PA Ringleb W Hacke EJ Topol 2002 Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus Am J Cardiol 90 625 628 10.1016/S0002-9149(02)02567-5 12231089 (Pubitemid 35264538)
35. TIMAD Study Group 1990 Ticlopidine treatment reduces the progression of non proliferative diabetic retinopathy Arch Ophtalmol 108 1577 1583
36. CAPRIE Steering Committee 1996 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1329 1339 10.1016/S0140-6736(96)09457-3 (Pubitemid 26383772)
37. JM Gaspoz PG Coxson PA Goldman LW Williams KM Duntz MG Hunink L Goldman 2002 Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary artery disease N Engl J Med 346 1819 1821 10.1056/NEJM200206063462309 (Pubitemid 34586917)
38. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators 2001 Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 494 502 10.1056/NEJMoa010746 (Pubitemid 32758501)
39. American College of Cardiology website: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: unstable angina/non-ST elevation myocardial infarction. Available at http://www.acc.org. Accessed 29 Sept 2002
40. G Davi C Patrono I Catalano N Custro C Giammarresi A Ganci F Cosentino A Notarbartolo 1993 Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus Arterioscler Thromb 13 1346 1349 8364018
41. A Giustina P Perini P Desenzani S Bossoni P Ianniello M Milani G Davi G Romanelli 1998 Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients Diabetes 47 423 430 10.2337/diabetes.47.3.423 9519749 (Pubitemid 28104205)
42. GG Neri-Serneri S Coccheri E Marubini F Violi 2004 For the committees and the investigators of the drug evaluation in atherosclerotic vascular disease in diabetics (DAVID) study group Eur Heart J 25 1845 1852 10.1016/j.ehj.2004.07. 013 15474700 (Pubitemid 39330236)
43. M Roffi DP Chew D Mukherjee DL Bhatt JA White C Heeschen, et al.. 2001 Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment elevation acute coronary syndrome Circulation 104 2767 2771 10.1161/hc4801.100029 11733392
44. DL Bhatt SP Marso M Lincoff, et al.. 2000 Abxicimab reduces mortality in diabetics following percutaneous coronary intervention J Am Coll Cardiol 35 922 928 10.1016/S0735-1097(99)00650-6 10732889 (Pubitemid 30189923)
45. C Patrono B Coller GA FitzGerald J Hirsh G Roth 2004 Platelet-active drugs: the relationships among dose, effectiveness, and side effects Chest 126 234S 264S 10.1378/chest.126.3-suppl.234S 15383474 (Pubitemid 39297956)
46. PA Gum K Kottke-Marchant PA Welsh, et al.. 2003 A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 961 965 10.1016/S0735-1097(02) 03014-0 12651041 (Pubitemid 36315537)
47. S Sanderson J Emery T Baglin AL Kinmonth 2005 Narrative review: aspirin resistance and its clinical implications Ann Intern Med 142 370 380 15738456
48. FM Pulcinelli S Riondino A Celestini P Pignatelli L Di Renzo F Violi 2005 Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin J Thromb Haemost 3 2784 2789 10.1111/j.1538-7836.2005. 01633.x 16359516 (Pubitemid 41819808)
49. C Hanjis WH Frishman RG Lerner 2006 Aspirin resistance: mechanisms and clinical implications Cardiol Rev 14 1 18 25 10.1097/01.crd.0000148175.60718.69 16371762 (Pubitemid 44378520)
50. SS Mehta RJ Silver A Aaronson M Abrahamson AB Goldfine 2006 Comparison of aspirin resistance in type I versus type 2 diabetes mellitus Am J Cardiol 97 567 570 10.1016/j.amjcard.2005.09.093 16461058 (Pubitemid 43190052)
51. G Di Minno F Violi 2004 Aspirin resistance and diabetic angiopathy: back to the future Thromb Res 113 97 99 10.1016/j.thromres.2004.02.017 15115664 (Pubitemid 38534486)
52. C Watala J Golanski J Pluta M Boncler M rozalski B Luzak A Kropiwnicka J Drzewoski 2004 Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control Thromb Res 113 101 113 10.1016/j.thromres.2003.12.016 15115665 (Pubitemid 38534487)
53. J Drezewoski C Watala 2004 Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care 27 5 1245 1246 10.2337/diacare.27.5.1245
54. C Watala J Pluta J Golanski M Rozalski M Czyz Z Trojanowski J Drzewoski 2005 Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin J Mol Med 83 148 158 10.1007/s00109-004-0600-x 15723265 (Pubitemid 40379303)
55. M Friend I Vucenik M Miller 2003 Research pointers: platelet responsiveness to aspirin in patients with hyperlipidaemia BMJ 326 82 83 10.1136/bmj.326.7380.82 12521973
56. G Davi P Alessandrini A Mezzetti G Minotti T Bucciarelli F Costantini, et al.. 1997 In vivo formation of 8-Epi- prostaglandin F2 alpha is increased in hypercholesterolemia Arterioscler Thromb Vasc Biol 17 3230 3235 9409316
57. GG Biondi-Zoccai A Abbate G Liuzzo, et al.. 2003 Atherothrombosis, inflammation and diabetes J Am Coll Cardiol 41 1071 1077 10.1016/S0735-1097(03) 00088-3 12679203 (Pubitemid 36384890)
58. TW Meade PJ Brennan 2000 Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial BMJ 321 13 17 10.1136/bmj.321.7252.13 10875825
59. F Catella-Lawson MP Reilly SC Kapoor, et al.. 2001 Cyclooxygenase inhibitors and the antiplatelet effects of aspirin N Engl J Med 345 1809 1817 10.1056/NEJMoa003199 11752357 (Pubitemid 34940862)
60. WC Lau LA Waskell PB Watkins, et al.. 2003 Atorvastatin reduces the ability of clopidogrel to inhibit platelet activation: a new drug-drug interaction Circulation 107 32 37 10.1161/01.CIR.0000047060.60595.CC 12515739 (Pubitemid 36070929)
61. ED Michos R Ardehali RS Blumenthal RA Lange H Ardehali 2006 Aspirin and clopidogrel resistance Mayo Clin Proc 81 4 518 526 10.4065/81.4.518 16610572
62. TA Nguyen JG Diodati C Pharard 2005 Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol 45 1157 1164 10.1016/j.jacc.2005.01.034 15837243 (Pubitemid 40523131)
63. DJ Angiolillo E Bernardo C Ramirez, et al.. 2006 Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment J Am Coll Cardiol 48 298 304 10.1016/j.jacc.2006.03.038 16843179 (Pubitemid 44026661)
64. D Sibbing, et al.. 2006 Diabetes mellitus and platelet function after administration of aspirin and a single 600 mg dose of clopidogrel J Thromb Haemost 4 2566 2568 10.1111/j.1538-7836.2006.02183.x 16938125 (Pubitemid 44741549)
65. DJ Angiolillo, et al.. 2007 Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of optimizing antiplatelet therapy in diabetes mellitus (OPTIMUS) study Circulation 11 708 716 10.1161/CIRCULATIONAHA.106.667741 (Pubitemid 46294761)
66. S Coccheri 2007 Approaches to prevention of cardiovascular complications and events in diabetes mellitus Drugs 67 7 997 1026 10.2165/00003495-200767070- 00005 17488145 (Pubitemid 46744476)
67. T Stys WE Lawson G Smaldone A Sys 2000 Does aspirin attenuate the beneficial effects of angiotensin converting enzyme inhibition in heart failure? Arch Int Med 160 1409 1413 10.1001/archinte.160.10.1409
68. J Leor H Reicher-Reiss U Goldbourt V Boyko S Gottlieb A Battler S Behar 1999 Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease J Am Coll Cardiol 33 1920 1925 10.1016/S0735-1097(99)00129-1 10362194
69. SF Dineen HC Gerstein 1997 The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus Arch Int Med 157 1413 1418 10.1001/archinte.157.13.1413
70. JR Sowers M Epstein 1995 Diabetes mellitus and associated hypertension, vascular disease and nephropathy Hypertension 26 869 879 7490142
71. M Trovati F Cavalot 2004 Optimization of hypolipidemic and antiplatelet treatment in the diabetic patient with renal disease J Am Soc Nephrol 15 S12 S20 10.1097/01.ASN.0000093238.09114.40 14684665
72. S Sagedal A Hartmann BjornsenS Sundstramk F Brosstad 2001 Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets Nephrol Dial Transplant 16 987 993 10.1093/ndt/16.5.987 11328905
73. RW Steiner C Coffins AD Carvalho 1979 Bleeding time in uremia: a useful test to assess clinical bleeding Am J Haematol 7 107 117 10.1002/ajh.2830070203 (Pubitemid 10165043)
74. G Di Minno J Martinez ML McKean, et al.. 1985 Platelet dysfunction in uremia Am J Med 79 552 559 10.1016/0002-9343(85)90051-8 3933340 (Pubitemid 16191207)
75. EP Evans RA Branch AL Bloom 1972 A clinical and experimental study of platelet function in chronic renal failure J Clin Pathol 25 745 753 10.1136/jcp.25.9.745 5086216
76. P Boccardo G Remuzzi M Galbusera 2004 Platelet dysfunction in renal failure Semin Thromb Hemost 30 579 589 10.1055/s-2004-835678 15497100 (Pubitemid 39426390)
77. M Livio A Benigni G Vigano, et al.. 1986 Moderate doses of aspirin and risk of bleeding in renal failure Lancet 1 414 416 10.1016/S0140-6736(86)92372-X 2868341
78. MG Shlipak PA Heidenreich H Noguchi GM Chertow WS Browner MB McClellan 2002 Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients Am Int Med 137 555 562
79. DN Reddan 2002 Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate cautions or the absence of data Am Heart J 144 206 207 10.1067/mhj.2002.125512 12177634 (Pubitemid 34879639)
80. NR Bulatova Yousef A MF SM AbuRuz 2007 Antiplatelet therapy for primary and secondary prevention in Jordanian patients with diabetes mellitus Thromb Res 121 43 50 10.1016/j.thromres.2007.03.006 17462716 (Pubitemid 350027773)
81. S Srikanth P Deedwania 2005 Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach Cardiol Clin 23 193 210 10.1016/j.ccl.2004.11.002 15694747 (Pubitemid 40203094)
82. SC Smith J Allen SN Blair, et al.. 2006 AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update JACC 47 2130 2139 16697342
83. V Evangelista L Totani S Rotondo R Lorenzet G Tognoni G De Berardis A Nicolucci 2005 Prevention of cardiovascular disease in type-2 diabetes: how to improve the clinical efficacy of aspirin Thromb Haemost 93 8 16 15630484
84. I Ikonomidis J Lekakis G Vamvakon F Andreotti P Nihoyannopulos 2005 Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with coronary artery disease: effects of aspirin treatment Am Heart J 149 832 839 10.1016/j.ahj.2004.08.030 15894964 (Pubitemid 40718878)
85. S Wong MC Morel- Kopp Q Chen M Appleberg CM Ward DR Lewis 2006 Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease Thromb Haemost 95 1042 1043 16732389
86. American Diabetes Association 2002 Clinical practice recommendations 2002, aspirin therapy in diabetes Diabetes Care 25(Suppl 1) S78 S79
87. C Perneby NH Wallen C Rooney D Fitzgerald P Hjemdahl 2006 Dose and time-dependent antiplatelet effects of aspirin Thromb Haemost 95 652 658 16601836
88. J Takahashi M Ushida R Komine A Shimizu T Uchida H Ishihara T Shibano G Watanabe Y Ikeda M Murata 2007 Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 119 517 524
89. SU Nowak LA Jaber 2003 Aspirin dose for prevention of cardiovascular disease in diabetics Am Pharmacother 37 116 121 10.1345/aph.1C101
90. JA Colwell 2005 Is aspirin effective in diabetic patients? Yes J Thromb Haemost 3 2612 2614 10.1111/j.1538-7836.2005.01719.x 16359499 (Pubitemid 41819785)
91. C Cimminiello 2005 Is aspirin effective in diabetic patients? No J Thromb Haemost 3 2615 2616 10.1111/j.1538-7836.2005.01720.x 16359500 (Pubitemid 41819786)
92. A Abaci Y Yilmaz M Caliskan F Bayram M Cetin A Unal S Cetin 2005 Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes Thromb Res 2005 116 465 470 10.1016/j.thromres.2005.02. 005 (Pubitemid 41330810)